Last updated on June 2019

Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.


Brief description of study

This is a Phase III, randomized, double-blind, placebo controlled, study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 treatment, compared to placebo, in patients with early stage TNBC at high risk for recurrence.

Clinical Study Identifier: NCT03562637

Find a site near you

Start Over

Pinnacle Research Group LLC

Anniston, AL United States
  Connect »

Clearview Cancer Institute

Huntsville, AL United States
  Connect »

Moores UCSD Cancer Center

La Jolla, CA United States
  Connect »

Miami Cancer Institute

Miami, FL United States
  Connect »

Advanced Research Institute, Inc.

New Port Richey, FL United States
  Connect »

Summit Cancer Care, PC

Savannah, GA United States
  Connect »

Henry Ford Medical Center

Detroit, MI United States
  Connect »

Austin Cancer Centers

Austin, TX United States
  Connect »

Blacktown Hospital

Blacktown, Australia
  Connect »

Gosford Hospital

Gosford, Australia
  Connect »

Luisen Hospital

Duesseldorf, Germany
  Connect »

Dong-A University Hospital

Busan, Korea, Republic of
  Connect »

National Cancer Center

Goyang-si, Korea, Republic of
  Connect »

Inha University Hospital

Incheon, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.